Predictors for Developing Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Following Infectious Mononucleosis.
Jason, Leonard A, Cotler, Joseph, Islam, Mohammed F et al. · Journal of rehabilitation therapy · 2022 · DOI
Quick Summary
This study followed 238 college students who developed infectious mononucleosis to see who would recover and who would develop ME/CFS. Researchers found that students who had stomach problems (pain, bloating, irritable bowel) before getting sick, combined with certain low immune markers and severe digestive symptoms when they got mononucleosis, had about an 80% chance of developing severe ME/CFS that lasted six months. This suggests that pre-existing gut problems and immune differences may help predict who is at highest risk.
Why It Matters
This is the first study to prospectively identify predictors of severe ME/CFS development following IM, offering potential for early identification of high-risk patients. Understanding which biological and symptom profiles predict severe outcomes could enable targeted interventions and improve clinical management of post-viral ME/CFS.
Observed Findings
Approximately 10% of IM patients developed ME/CFS symptoms persisting at 6 months (48 out of 238).
Of those with post-IM ME/CFS, 63% were classified as severe (30 moderate, 18 severe).
Students with pre-illness gastrointestinal symptoms AND abnormally low IL-13 and/or IL-5 levels had approximately 80% risk of developing severe ME/CFS.
Pre-illness gastrointestinal distress was more common in students who later developed severe ME/CFS than in those who recovered.
Severe gastrointestinal symptoms during acute IM infection were associated with ME/CFS persistence.
Inferred Conclusions
Pre-existing gastrointestinal dysfunction combined with baseline immune markers (low IL-13/IL-5) may identify patients at substantially elevated risk for severe ME/CFS following IM.
Gastrointestinal and autonomic symptom severity, along with specific immune dysregulation, appear mechanistically linked to severe post-viral ME/CFS development.
Baseline immune profiling and symptom history could potentially enable early identification and stratification of IM patients at high risk for ME/CFS.
Remaining Questions
Why specifically IL-13 and IL-5 deficiency predispose to severe ME/CFS, and what their functional role is in pathophysiology.
What This Study Does Not Prove
This study does not prove that gastrointestinal symptoms or low IL-13/IL-5 directly cause ME/CFS; it only shows these factors are associated with higher risk. The findings apply specifically to ME/CFS following mononucleosis and may not generalize to ME/CFS from other infectious triggers or non-infectious origins. The study cannot determine whether these markers are causal mechanisms or simply biomarkers of predisposition.